INSP vs. PODD, TFX, SOLV, GMED, PEN, GKOS, MMSI, HAE, AXNX, and PRCT
Should you be buying Inspire Medical Systems stock or one of its competitors? The main competitors of Inspire Medical Systems include Insulet (PODD), Teleflex (TFX), Solventum (SOLV), Globus Medical (GMED), Penumbra (PEN), Glaukos (GKOS), Merit Medical Systems (MMSI), Haemonetics (HAE), Axonics (AXNX), and PROCEPT BioRobotics (PRCT). These companies are all part of the "surgical & medical instruments" industry.
Insulet (NASDAQ:PODD) and Inspire Medical Systems (NYSE:INSP) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.
Insulet presently has a consensus price target of $239.18, suggesting a potential upside of 23.73%. Inspire Medical Systems has a consensus price target of $235.29, suggesting a potential upside of 87.05%. Given Insulet's higher possible upside, analysts clearly believe Inspire Medical Systems is more favorable than Insulet.
In the previous week, Insulet had 8 more articles in the media than Inspire Medical Systems. MarketBeat recorded 22 mentions for Insulet and 14 mentions for Inspire Medical Systems. Inspire Medical Systems' average media sentiment score of 0.99 beat Insulet's score of 0.94 indicating that Insulet is being referred to more favorably in the media.
Insulet has higher revenue and earnings than Inspire Medical Systems. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.
Insulet has a net margin of 13.14% compared to Insulet's net margin of -2.38%. Inspire Medical Systems' return on equity of 34.06% beat Insulet's return on equity.
94.9% of Inspire Medical Systems shares are held by institutional investors. 0.5% of Insulet shares are held by insiders. Comparatively, 4.1% of Inspire Medical Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Insulet has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.
Insulet received 535 more outperform votes than Inspire Medical Systems when rated by MarketBeat users. Likewise, 66.05% of users gave Insulet an outperform vote while only 60.88% of users gave Inspire Medical Systems an outperform vote.
Summary
Insulet beats Inspire Medical Systems on 14 of the 18 factors compared between the two stocks.
Get Inspire Medical Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for INSP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inspire Medical Systems Competitors List
Related Companies and Tools
